Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Pharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks...

Cipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growin...

Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics ...

Under the terms of the agreement, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product develo...

Cipla’s shares hit a record high of Rs 814.45 on Monday before ending at Rs 795.65, up 9.2 per cent from the previous close. Cipla reported...

Elaborating on the pipeline for new drugs, Cipla said it has over 200 drugs under development with the top 50 projects having potential of ...

Cipla has inked a pact with Biopharma SPA for establishing a joint venture company in Algeria to manufacture and market respiratory product...

Cipla has entered into an agreement with Biopharm SPA to form a joint venture company in Algeria to manufacture and market respiratory prod...

Cipla said this collaboration will enable it to focus on its core therapy areas, while S&D Pharma will be the key partner for generics.

Pharmaceutical firm Cipla today announced commercial collaboration with UK-based S&D Pharma in the Czech Republic and Slovakia.

Under the contract, which will run from July 2014 to April 2017, the company will supply drugs including Beclate 100, Becalate 200 and Asth...

Cipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...